BioWisdom unveils new partner in safety intelligence programme

Published: 4-Mar-2008

Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) has become the second partner in BioWisdom\'s Safety Intelligence Program (SIP). The first partner was AstraZeneca.


Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) has become the second partner in BioWisdom's Safety Intelligence Program (SIP). The first partner was AstraZeneca.

J&JPRD, a division of Janssen Pharmaceutica, will help use BioWisdom's Sofia technology to deliver a specialist medical search system to support drug safety risk assessment at all stages of pharmaceutical R&D.

BioWisdom is a market leader in ontology-powered intelligence solutions for the healthcare industry. J&JPRD will join BioWisdom's SIP board as part of the three-year partnership.

"We are delighted to have J&JPRD join our Safety Intelligence Program and look forward to working closely with safety assessment teams across the organisation and affiliates," said Dr. Julie Barnes, chief scientific Officer of BioWisdom. "This second partnership is a testimony to the value that the pharmaceutical industry sees in our approach to drug safety and risk management."

SIP board chairman Dr Jack Reynolds, said: "I look forward to working with all partners on the SIP board to advance the SIP for the purpose of improving our understanding of many of the major recurring and potentially serious drug-induced adverse events."

The financial details of the deal have not been disclosed.

See more

You may also like

Manufacturing

Johnson & Johnson to invest $55bn into US manufacturing, R&D and tech

Read more
The company will build three new advanced pharmaceutical manufacturing facilities on top of its biologics manufacturing site in Wilson, North Carolina, which is currently under construction

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Johnson & Johnson to invest $55bn into US manufacturing, R&D and tech

The company will build three new advanced pharmaceutical manufacturing facilities on top of its biologics manufacturing site in Wilson, North Carolina, which is currently under construction
Finance

Johnson & Johnson to bolster neuroscience portfolio with $14.6bn Intra-Cellular Therapies acquisition

Through this potential acquisition, Johnson & Johnson will add schizophrenia and bipolar drug Caplyta to its portfolio, as well as a range of clinical candidates designed to treat neurological diseases
Finance

Johnson & Johnson completes V-Wave acquisition to support patients with heart failure

The strategic acquisition will bolster the pharma giant's MedTech offerings for patients with cardiovascular disease
Regulatory

Johnson & Johnson submits nipocalimab application to the FDA following positive Phase III results

The drug — in combination with the standard of care regimen — was able to exhibit sustained disease control over the 24 week trial period
Regulatory

Johnson & Johnson's Rybrevant-Lazcluze combo receives FDA approval for EGFR-mutated lung cancer

The combination therapy was seen to reduce risk of disease progression or death by 30% compared to the current standard of care, osimertinib
Finance

Johnson & Johnson to acquire heart failure specialist, V-Wave, for up to $1.1bn

The strategic acquisition will boost J&J's offering in the heart disease category
Regulatory

Johnson & Johnson seeks approval for subcutaneous formulation of Rybrevant to treat EGFR-mutated NSCLC

The submission to the EMA is supported by data from the Phase III PALOMA-3 study, which showed the non-inferiority of subcutaneous Rybrevant to intravenous administration
Subscribe now